Plasma superwarfarin levels and vitamin K1 treatment in dogs with anticoagulant rodenticide poisoning

被引:21
|
作者
Robben, JH
Kuijpers, EAP
Mout, HCA
机构
[1] Univ Utrecht, Fac Vet Med, Dept Clin Sci Compan Anim, Intens Care Unit, NL-3508 TD Utrecht, Netherlands
[2] Leiden Univ, Med Ctr, Dept Clin Pharm & Toxicol, Leiden, Netherlands
[3] Natl Inst Publ Hlth & Environm, Natl Poisons Control Ctr, NL-3720 BA Bilthoven, Netherlands
关键词
D O I
10.1080/01652176.1998.9694831
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
The plasma concentration, plasma half-life (t(1/2)), and mean residence time (MRT) of rodenticide anticoagulants were determined in 21 dogs in which a preliminary diagnosis of anticoagulant rodenticide poisoning had been made. Brodifacoum, difethialone, and difenacoum were detected by high-performance liquid chromatography (HPLC) in the plasma of 13, 3, and 2 dogs, respectivery. At presentation the plasma concentration ranged from below the detection limit (10 ng/L) to 851 ng/L. Toxin could not be detected in 3 dogs, despite these animals showing characteristic coagulation disturbances and a positive response to therapy with vitamin K-1. In 7 dogs the estimated t(1/2) of brodifacoum ranged from 0.9 to 4.7 (median 2.4) days with a MRT of 1.9 to 3.7 (median 2.8) days. In 2 dogs the individual t(1/2) Of difethialone was 2.2 and 3.2 days and the MRT was 2.3 and 2.8 days, respectively. Two dogs died during emergency treatment. Treatment in the remaining 19 dogs consisted of the administration of vitamin K-1 and supportive therapy. The dose of vitamin K-1 was reduced in a stepwise manner as long as the prothrombin time remained within physiological limits. The variation in initial plasma concentrations of the anticoagulants combined with the results of treatment support the idea that an individual therapeutic approach is warranted.
引用
收藏
页码:24 / 27
页数:4
相关论文
共 50 条
  • [21] VITAMIN K1
    MACINTOSH, AM
    MEDICAL JOURNAL OF AUSTRALIA, 1971, 2 (16) : 828 - +
  • [22] VITAMIN K1 AND VITAMIN K ANALOGUES
    FINKEL, MJ
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1961, 2 (06) : 794 - +
  • [23] A retrospective evaluation of vitamin K1 therapy to reverse the anticoagulant effect of warfarin
    Fan, JY
    Armitstead, JA
    Adams, AG
    Davis, GA
    PHARMACOTHERAPY, 2003, 23 (10): : 1245 - 1250
  • [24] Routine Micromethod for the Determination of Vitamin K1 in Human Plasma
    Meineke, Ingolf
    Willnow, Cornelia
    Stingl, Julia
    Brockmoeller, Juergen
    THERAPEUTIC DRUG MONITORING, 2013, 35 (06) : 859 - 862
  • [25] Plasma lipoproteins as carriers of phylloquinone (vitamin K1) in humans
    Lamon-Fava, S
    Sadowski, JA
    Davidson, KW
    O'Brien, ME
    McNamara, JR
    Schaefer, EJ
    AMERICAN JOURNAL OF CLINICAL NUTRITION, 1998, 67 (06): : 1226 - 1231
  • [26] Superwarfarin poisoning should be considered in patients with vitamin K deficiency unresponsive to therapy.
    Rauch, TM
    Marques, MB
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2004, 122 (03) : 466 - 466
  • [27] A derivative of vitamin K1
    Almquist, HJ
    Klose, AA
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1939, 130 (02) : 791 - 793
  • [28] Vitamin K1 in therapeutics
    Buxeraud, Jacques
    Faure, Sebastien
    ACTUALITES PHARMACEUTIQUES, 2022, 61 (621): : 23 - +
  • [29] VITAMIN K1 IN CHLOROPLASTS
    KEGEL, LP
    CRANE, FL
    NATURE, 1962, 194 (4835) : 1282 - &
  • [30] Synthesis of vitamin K1
    Klose, AA
    Almquist, HJ
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1940, 132 (01) : 469 - 470